Facial fine wrinkles, enlarged pores, and skin laxity in healthy individuals seeking facial rejuvenation. The study focuses on age-related skin changes equally present on both sides of the face. Platelet-rich plasma, Platelet-rich fibrin, Skin rejuvenation
Conditions
Interventions
Participants in this group received injections of Platelet-Rich Plasma (PRP) on the right side of the face and Platelet-Rich Fibrin (PRF) on the left side. PRP was prepared by collecting 10 mL of bloo
Platelet-Rich Plasma (PRP) Injection,Platelet-Rich Fibrin (PRF) Injection
Sponsors
Institute of dermatology, Thailand
Eligibility
Sex/Gender
All
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Age between 30 and 50 years 2. Presence of fine wrinkles, enlarged pores, and facial skin laxity on both sides of the face 3. Ability to read and communicate clearly in Thai
Exclusion criteria
Exclusion criteria: 1. Currently enrolled in another ongoing research study 2. Regular alcohol consumers or smokers 3. Occasional alcohol consumers or smokers who drank or smoked within one month before the study 4. Pregnant or breastfeeding women 5. Women receiving hormone therapy or taking oral contraceptives 6. History of allergy to platelet-rich plasma, platelet-rich fibrin, sodium citrate, or topical anesthetics used before treatment 7. Individuals with bleeding disorders or platelet function abnormalities 8. History of blood-borne infectious diseases such as hepatitis B, hepatitis C, or HIV 9. Presence of other facial skin diseases such as infections, skin cancer, or dermatitis 10. Individuals with any chronic diseases or medical conditions except: 10.1. Allergic rhinitis (without current flare-up or regular medication) 10.2. Peptic ulcer disease (without regular medication) 10.3. Migraine (non-chronic and without regular medication) 11. Individuals with inflammatory or infectious diseases or immune-related disorders such as AIDS, tuberculosis, diabetes, or liver disease 12.Use of isotretinoin, vitamin A, vitamin C, vitamin E, or other antioxidants (topical or oral) within three months before treatment 13. Individuals who will receive corticosteroids (oral, injectable, or topical on the face), chemotherapy, or anticoagulants during the study period 14. History of botulinum toxin, filler, stem cell, platelet-rich plasma injection, or deep-tissue laser treatment within six months before treatment 15. History of intravenous vitamin or nutrient infusion for skin rejuvenation within three months before treatment 16. History of exosome therapy, chemical peeling, laser resurfacing, microdermabrasion, or other exfoliating procedures within three months before treatment 17. History of hypertrophic scarring or keloid-prone skin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fine wrinkle at baseline, 1 month, and 4 month after end of the intervention Antera 3D camera for fine wrinkle assessment,Pore size at baseline, 1 month, and 4 month after end of the intervention Antera 3D camera for pore size measurement,Elasticity at baseline, 1 month, and 4 month after end of the intervention Cutometer MPA 580 for skin elasticity evaluation | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction 4 month after end of the intervention Patient satisfaction questionnaire at 4 months post-treatment ,Side effect 1 day and 3 day after each injection Adverse effects checklist including redness, pain, itching, and swelling | — |
Countries
Thailand
Contacts
Public ContactVarisa Ramkul
Institute of dermatology
Outcome results
None listed